Wegovy vs Zepbound
GLP-1 Receptor Agonist (semaglutide 2.4mg) · Dual GIP/GLP-1 Receptor Agonist (tirzepatide)
Here is how these two compounds compare, based on published research, not marketing claims.
Wegovy
Novo Nordisk's brand of high-dose semaglutide. FDA-approved for chronic weight management. The only obesity-indicated medication with completed cardiovascular outcomes data through the SELECT trial.
Zepbound
Eli Lilly's brand of tirzepatide for weight management. FDA-approved for chronic weight management. The first dual GIP and GLP-1 receptor agonist for obesity, with the largest weight reduction shown in any approved weight-loss medication.
Wegovy
4520 studies
39 human trials
FDA-Approved
Zepbound
1849 studies
47 human trials
FDA-Approved
What it does
Wegovy
Wegovy is the Novo Nordisk brand of high-dose semaglutide (2.4mg) indicated by the FDA for chronic weight management in adults with obesity or overweight with at least one weight-related condition. It works by telling the brain the body is full and slowing how fast the stomach empties, with the larger dose producing more pronounced appetite suppression than lower-dose semaglutide does for type 2 diabetes. The same active ingredient is sold as Ozempic at lower doses, with FDA approval for type 2 diabetes management.
Zepbound
Zepbound is the Eli Lilly brand of tirzepatide indicated by the FDA for chronic weight management in adults with obesity or overweight with at least one weight-related condition. It activates two appetite and metabolism receptors at once (GIP and GLP-1) instead of just one, the dual mechanism that distinguishes tirzepatide from semaglutide. The same active ingredient is sold as Mounjaro at lower-titration ranges, with FDA approval for type 2 diabetes management.
How it works
Wegovy
Wegovy delivers semaglutide at a higher dose than its sibling brand Ozempic. The molecule activates the GLP-1 receptor in the brain and gut, which tells the brain the body is full, slows how fast the stomach empties, and helps the pancreas regulate blood sugar. At the higher Wegovy dose, GLP-1 receptors in the hypothalamus are more strongly activated than at typical Ozempic diabetes doses, producing the pronounced appetite suppression observed across the STEP trial program.
Zepbound
Zepbound delivers tirzepatide, a synthetic peptide that acts as an agonist at both GIP receptors and GLP-1 receptors simultaneously. The GLP-1 side mirrors what semaglutide does: tells the brain the body is full, slows gastric emptying, helps the pancreas regulate blood sugar. The GIP side adds enhanced fat metabolism and may distribute the pharmacological load across two receptor systems. The dual mechanism produced larger mean body weight reduction than semaglutide in the SURMOUNT-5 head-to-head trial.
How often
Wegovy
FDA labeling specifies once-weekly subcutaneous injection from a pre-filled pen for Wegovy. The STEP trial protocols and FDA prescribing information specify gradual dose titration over several months, which the labeling notes is associated with improved GI tolerability. Wegovy is the higher-dose semaglutide formulation specifically for weight management; the lower-dose semaglutide formulation for type 2 diabetes is marketed as Ozempic.
Zepbound
FDA labeling specifies once-weekly subcutaneous injection from a pre-filled pen for Zepbound. The SURMOUNT trial protocols and FDA prescribing information specify gradual dose titration over several months, which the labeling notes is associated with improved GI tolerability. Zepbound is the obesity-indicated brand of tirzepatide; the diabetes-indicated brand is marketed as Mounjaro.
How strong
Wegovy
Strong appetite suppression and meaningful weight reduction at FDA-approved doses for chronic weight management. The STEP 1 trial demonstrated approximately 15% mean body weight reduction over 68 weeks. The SELECT trial extended the case to cardiovascular outcomes, demonstrating reduction in major adverse cardiovascular events in adults with overweight or obesity and established cardiovascular disease. Patients commonly experience pronounced satiety and slower gastric emptying as the dose titrates up.
Zepbound
Among the largest weight reductions reported for any FDA-approved pharmacological agent at the time of approval. The SURMOUNT-1 trial demonstrated approximately 20.9% mean body weight reduction at 72 weeks at the highest dose. Patients commonly experience pronounced appetite suppression and reduced food preoccupation as the dose titrates up. The dual GIP plus GLP-1 mechanism produces effects that GLP-1-only obesity medications do not fully replicate, including the larger weight-loss numbers seen in SURMOUNT-1 and SURMOUNT-5.
Main tradeoff
Wegovy
Wegovy carries the cardiovascular outcomes data that no other obesity-indicated medication has matched: the SELECT trial demonstrated meaningful CV-event reduction in adults with overweight or obesity and established cardiovascular disease. Common side effects are GI: nausea, vomiting, diarrhea, usually transient and dose-dependent. Tirzepatide (Zepbound) produced larger average weight reductions in the SURMOUNT-5 head-to-head trial, but Wegovy remains the only obesity-indicated medication with completed cardiovascular outcomes data. Bone mineral density may decrease modestly with significant weight loss; the effect is class-shared with tirzepatide and appears weight-loss-mediated rather than drug-specific (Liu et al. 2026). In adults without diabetes (Wegovy's primary brand population), the GLP-1 RA group lost modestly more bone density at the total hip than matched controls (-1.0% vs -0.6% over 17 months).
Zepbound
Zepbound produced larger mean body weight reduction than Wegovy in head-to-head data (SURMOUNT-5). The trade-off is evidence maturity: tirzepatide is newer than semaglutide, with less long-term safety data and no completed cardiovascular outcomes trial yet for the obesity indication (the SURPASS-CVOT diabetes trial is ongoing). Common side effects are GI: nausea, vomiting, diarrhea, similar in pattern to GLP-1 agonists but potentially differing due to dual-receptor activity. Bone mineral density may decrease modestly with significant weight loss; the effect is class-shared with semaglutide and appears weight-loss-mediated rather than drug-specific (Liu et al. 2026). In adults without diabetes (Zepbound's primary brand population), the GLP-1 RA group lost modestly more bone density at the total hip than matched controls (-1.0% vs -0.6% over 17 months).
Best for
Wegovy
- Adults with obesity or overweight plus established cardiovascular disease prioritizing the SELECT outcomes data
- Patients seeking the obesity-indicated GLP-1 with the longest real-world safety record
- Clinical contexts where insurance covers Wegovy but not Zepbound at preferred-tier
Zepbound
- Adults with obesity or overweight seeking the largest weight reduction shown in head-to-head obesity data (SURMOUNT-5)
- Patients seeking the dual GIP plus GLP-1 mechanism for combined appetite and metabolic effect
- Clinical contexts where insurance covers Zepbound but not Wegovy at preferred-tier
How to choose
A good fit for Wegovy
- Adults with obesity or overweight plus established cardiovascular disease where the SELECT outcomes data is decision-relevant
- Patients prioritizing the obesity-indicated GLP-1 with the longest real-world safety record and most mature post-marketing surveillance
- Insurance contexts where Wegovy is the preferred-tier formulary option for obesity
- Patients seeking single-receptor (GLP-1) pharmacology with established class-wide post-marketing data
A good fit for Zepbound
- Adults with obesity or overweight seeking the largest weight reduction shown in head-to-head obesity data (SURMOUNT-5)
- Patients seeking the dual GIP plus GLP-1 mechanism for combined appetite and metabolic effect
- Insurance contexts where Zepbound is the preferred-tier formulary option for obesity
- Adults with obesity or overweight prioritizing the dual GIP/GLP-1 mechanism over semaglutide's longer post-marketing safety record and completed cardiovascular outcomes data
Consider both across time
Wegovy and Zepbound are both FDA-approved for chronic weight management at the same eligibility thresholds (BMI ≥ 30, or BMI ≥ 27 with at least one weight-related condition). The choice often comes down to insurance coverage, formulary tier, physician familiarity, and prior treatment history. Tirzepatide produced larger mean body weight reduction in head-to-head data (SURMOUNT-5), but semaglutide has cardiovascular outcomes data tirzepatide hasn't matched yet through SELECT. For the type 2 diabetes-indicated formulations of the same active ingredients, see Ozempic vs Mounjaro. For the underlying compound comparison covering the full evidence base across both indications, see Semaglutide vs Tirzepatide.
Dosing should be determined by a qualified physician who can evaluate individual circumstances. PSI does not provide personalized dosing guidance.
Official dosing references
- DailyMed(NIH drug labels)
- ClinicalTrials.gov
- PubMed
For readers who want the biology: here is the pathway each compound uses to signal the body. This section is optional. The comparison above covers the practical differences.
▶See the biology
- GLP-1 Receptor
- GLP-1 Receptor activates GLP-1 Signaling
- GLP-1 Signaling connects to Appetite + Gastric Emptying
- GLP-1 Signaling connects to Glucose Control
- Appetite + Gastric Emptying connects to Weight + Glycemic Outcomes; Glucose Control connects to Weight + Glycemic Outcomes; Appetite + Fat Metabolism connects to Weight + Glycemic Outcomes
- GIP Receptor
- GLP-1 Receptor activates Dual GIP + GLP-1 Signaling; GIP Receptor activates Dual GIP + GLP-1 Signaling
- Dual GIP + GLP-1 Signaling connects to Appetite + Fat Metabolism
Wegovy (high-dose semaglutide) activates the GLP-1 receptor in the brain and gut, which tells the brain the body is full and slows how fast the stomach empties.
Zepbound (tirzepatide) activates both GLP-1 and GIP receptors at once. The GLP-1 side mirrors Wegovy; the GIP side adds enhanced fat metabolism.
Research Evidence
Both Wegovy and Zepbound sit at PSI's highest evidence tier (FDA Approved). Wegovy has the deeper, longer obesity-specific evidence base: the STEP program established efficacy across multiple populations, and SELECT extended the case to cardiovascular outcomes in adults with overweight or obesity and established cardiovascular disease. Zepbound's evidence base is substantial but newer: the SURMOUNT program established efficacy for chronic weight management, with SURMOUNT-5 providing direct head-to-head data versus semaglutide for the obesity indication. SURMOUNT-5 demonstrated larger mean body weight reduction with tirzepatide than with semaglutide; the comparable cardiovascular outcomes trial for tirzepatide in obesity is not yet completed.
- 1.
For adults with obesity or overweight plus established cardiovascular disease, Wegovy has the SELECT trial outcomes data; no comparable Zepbound trial has been completed for the obesity indication.
- 2.
For adults seeking the largest weight reduction shown in head-to-head obesity data, Zepbound produced larger mean reductions than Wegovy in SURMOUNT-5.
- 3.
For type 2 diabetes as the primary clinical goal, the FDA-approved formulations of these compounds are sold under different brand names: Ozempic (semaglutide) and Mounjaro (tirzepatide).
- 4.
Both brands require physician prescription, ongoing supervision for dose titration, side effect monitoring, and discontinuation planning. Insurance coverage and physician familiarity often drive the practical brand choice.
Key Limitations
- •SURMOUNT-5 head-to-head compared tirzepatide to semaglutide 2.4mg over 72 weeks; the 72-week duration limits inference about longer-term differential outcomes.
- •No completed cardiovascular outcomes trial yet exists for tirzepatide in the obesity-indicated population.
- •Long-term (5+ year) post-marketing safety data is more mature for semaglutide than for tirzepatide.
- •Insurance coverage, formulary tier, and supply constraints affect real-world access and may influence prescribing decisions independent of efficacy data.
- •Compounded versions of both active ingredients are not FDA-approved and are subject to pharmacy regulations that have changed multiple times since 2023.
Community Discussion
PSI monitors discussions across peptide research and biohacking communities. These are reported experiences, not clinical evidence.
Wegovy
"I lost 30+ pounds on Ozempic without changing anything else"
Supported by evidence
"Ozempic face is a real thing. I look ten years older"
Supported by evidence
"The nausea goes away after a few weeks"
Supported by evidence
Zepbound
"Mounjaro is stronger than Ozempic for weight loss"
Supported by evidence
"The dual agonist mechanism is why it works better"
Supported by evidence
"Tirzepatide has fewer GI side effects than semaglutide"
Plausible but limited comparison data
Safety Comparison
Both share the GLP-1 class side effect profile: nausea, vomiting, diarrhea, usually transient and dose-dependent, and manageable with slow dose titration. Both carry the FDA boxed warning for thyroid C-cell tumors based on rodent studies; clinical relevance in humans remains debated. Wegovy has the longer real-world safety record and more extensive post-marketing surveillance through Novo Nordisk's pharmacovigilance program. Zepbound's dual-receptor mechanism is newer; long-term safety is still being characterized as more years of post-approval data accumulate. On bone density: both compounds appear to cause modest bone mineral density loss in head-to-head data (Liu et al. 2026, J Clin Endocrinol Metab), with the loss correlating with weight loss within the GLP-1 RA group rather than a direct drug effect. The finding is particularly relevant for the brand populations of Wegovy and Zepbound: in adults without diabetes (the predominant population for chronic weight management), the GLP-1 RA group lost modestly more bone density at the total hip than matched controls (-1.0% vs -0.6% over 17 months); in adults with diabetes, the loss matched controls. Compounded versions of either active ingredient are not FDA-approved and have been associated with dosing errors and quality concerns outside the FDA-regulated supply chain.
Wegovy
Well-characterized safety profile from the STEP program plus SELECT cardiovascular outcomes trial. Most common adverse events are GI-related: nausea, vomiting, diarrhea, typically transient and dose-dependent. FDA boxed warning for thyroid C-cell tumors based on rodent studies; clinical relevance in humans debated. Rare risks include pancreatitis.
Zepbound
Safety profile from the SURMOUNT program. GI adverse events similar in pattern to GLP-1 agonists but potentially differing due to dual-receptor activity. FDA boxed warning for thyroid C-cell tumors based on rodent studies. Long-term post-marketing data is growing but less extensive than semaglutide's.
What the Research Suggests
Wegovy and Zepbound are both FDA-approved chronic weight management medications at the highest evidence tier. The choice between them is rarely about whether they work for weight loss: both do, with strong randomized controlled trial evidence. It's about which evidence profile matches the clinical question. Zepbound produced larger mean body weight reduction than Wegovy in head-to-head SURMOUNT-5 data. Wegovy has cardiovascular outcomes data Zepbound has not matched yet. For patients searching by brand name without realizing the FDA-approved indication is chronic weight management (not type 2 diabetes), the appropriate diabetes-indicated brands are Ozempic and Mounjaro. PSI does not endorse one brand over the other; the appropriate choice depends on the individual clinical context, which a physician evaluates.